Insulin Degludec Noninferior to Glargine for CV Events in T2DM
The researchers found that the primary outcome of first occurrence of an adjudicated major cardiovascular event occurred in 8.5% and 9.3% of patients in the degludec and glargine groups, respectively.
(HealthDay News) — Among high-risk patients with type 2 diabetes, degludec is noninferior to glargine in terms of the incidence of cardiovascular events, according to a study published online in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Diabetes Association, held from June 9 to 13 in San Diego.
Steven P. Marso, MD, from the Research Medical Center in Kansas City, Mo., and colleagues randomized 7637 patients with type 2 diabetes (85.2% with established cardiovascular disease, chronic kidney disease, or both) to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime.
The researchers found that the primary outcome of first occurrence of an adjudicated major cardiovascular event occurred in 8.5% and 9.3% of patients in the degludec and glargine groups, respectively (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P <.001 for noninferiority). The mean glycated hemoglobin level was 7.5 ± 1.2 percent in each group at 24 months, while the degludec group had a significantly lower mean fasting plasma glucose level (128 ± 56 vs 136 ± 57 mg/dL; P <.001). There was no between-group difference in the rates of adverse events.
"Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events," the authors write.
The study was funded by Novo Nordisk, the manufacturer of degludec.
- Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 12 June 2017. doi: 10.1056/NEJMoa1615692